What type of sample is needed – just aspirates and a typical flow sample?

We need about 10 million cancer cells to run the full chemosensitivity panel so we ask that you conduct an aggressive woodpecker style FNA, poking as many nodes as possible and putting the cells into our proprietary media tubes (ensures we receive live cells), then of course we need a whole blood sample (2mL).

Other Questions

Back to Help Center

For patients who already have flow cytometry, can you just run the drug sensitivity profile?

No, we cannot run a drug sensitivity-only service. Please understand our AI-based drug response prediction models require flow cytometry and PARR parameters generated from our own instrumental setting. Even if the patient already has flow cytometry results from another laboratory, we need to run flow and PARR again anyway.

If the blood clots can the ImpriMed test still be run?

Blood clots can prevent our ability to run our tests. Very small clots may not be a problem, but in general, clotted blood is not ideal. That is why we ask that doctors send blood in an EDTA or heparin tube.

When will I be billed? Are we billed at the same time as placing the order?

Invoices will be sent about 30 days after the service is ordered. We send the invoice to the email (billing or accounts payable) we have on file for the clinic at the start of the month for any services provided the month prior.

Does pet insurance cover ImpriMed?

Most pet insurance plans that cover cancer care will typically cover ImpriMed’s services. Please check with your insurance representative to see if your plan can cover the services.

What does the ImpriMed Personalized Prediction Profile include?

The Personalized Prediction Profile includes our Immunoprofile report and anticancer drug response predictions generated by artificial intelligence models. The predictions include estimates of both (1) the likelihood of a positive clinical response (partial response/ complete remission) to individual anticancer drugs and (2) the likelihood complete remission after 1 or 2 cycles of CHOP therapy, and the likelihood of early relapse after a successful CHOP regimen. Outcome predictions are currently provided for 13 individual drugs that are commonly used in many first-line and rescue protocols for the treatment of canine lymphoma (including CHOP, LOPP, MOPP, LPP, Tavonea only, etc…). Predictions are included for Doxorubicin, Cyclophosphamide, Vincristine, Vinblastine, Prednisone, Rabacfosadine (Tanovea®), L-Asparaginase, Lomustine, Mitoxantrone, Mechlorethamine, Dexamethasone, Chlorambucil, and Melphalan.